PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Unlike semaglutide, ecnoglutide preferentially targets the production of cyclic adenosine monophosphate, a messenger molecule associated with regulating glycogen, sugar and lipid metabolism ... such ...

Entering your 30s signals subtle bodily changes, increasing the risk of chronic diseases like diabetes and hypertension.

Science has finally caught up with ancient wisdom. Apples, especially the Golden Delicious variety, are not just filler ...

How much alcohol consumption is too much? The WHO, the American Institute for Cancer Research, World Cancer Research Fund and ...

University of Texas Southwestern Medical Center scientists found that activating fibroblast growth factor 21 (FGF21) ...

Discover how the new technique of HSMP can help scientists gain insights into the world of biological processes and their ...

China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management: San Francisco, US Monday, June 30, 2025, 12:00 Hrs [IST] Innovent ...

SAN FRANCISCO, CA, USA and SUZHOU, China I June 27, 2025 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical ...